US Stock MarketDetailed Quotes
LRTX Lirum Therapeutics
- 0.000
- 0.0000.00%
Close Sep 27 09:30 ET
0Market Cap0.00P/E (TTM)
0.000High0.000Low0Volume0.000Open0.000Pre Close0.00Turnover0.00%Turnover Ratio0.00P/E (Static)9.27MShares0.00052wk High0.00P/B0Float Cap0.00052wk Low--Dividend TTM4.58MShs Float0.000Historical High--Div YieldTTM0.00%Amplitude0.000Historical Low--Avg Price1Lot Size
About Lirum Therapeutics Company
Lirum Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which focuses on the treatment of deliberating diseases. The firm is also involved in the acquisition, development, and commercialization of drug candidates. Its products include LX-101, a targeted therapy directed to the insulin-like growth factor 1 (IGF-1R). The company was founded in November 2021 and is headquartered in New York, NY.
Company Profile
SymbolLRTX
Company NameLirum Therapeutics
Founded2021
CEOMr. Peter McDonald
MarketNASDAQ
Employees3
Fiscal Year Ends12-31
Address590 Madison Avenue,21st floor
CityNew York
ProvinceNew York
CountryUnited States of America
Zip Code10022
Phone1-646-964-1402
Websitehttp://www.lirumtx.com
Company Executives
- Name
- Position
- Salary
- Peter McDonald
- Chief Executive Officer, Interim Principal Financial and Accounting Officer
- --
- Dr. Ivan Bergstein
- Chairman of the Board
- --
- Kenneth Hoberman
- Vice Chairman of the Board
- --
- Alan S. Forman
- Independent Director
- --
- Mark Sard
- Independent Director
- --
- Kenneth J. Zuerblis
- Independent Director
- --
- Daniel Hume
- Independent Director
- --
Analysis
Price Target
No Data
Heat List
US
Overall
Symbol
Latest Price
% Chg
No Data